Compare Newmont Corporation (NEM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Zoetis Inc — how do they compare? Newmont Corporation trades at $93.93 (market cap $95.23B), while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Newmont Corporation is far larger — about 3× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| NEM | ZTS | |
|---|---|---|
Market Cap | $95.23B | $31.95B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $156.76 |
52-Week Low | $59.86 | $71.91 |
Enterprise Value | $91.98B | $39.24B |
Dividend Yield | 1.17% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont (NEM) trades at $92.49, up 3.11% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Revenue grew to $22.67B in 2025, net income surged to $7.09B, and cash flow from operations hit $10.33B. Analyst consensus is strongly bullish with a $134.63 price target, though technical indicators show selling pressure near resistance at $92.
The outlook is positive given robust profitability, low P/E of 11.57, and gold price tailwinds, but risks include rising unit costs and production volatility. With 76% of analysts rating it Buy and institutional interest steady, NEM offers value if operational execution holds.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
